Home » »

|| Chinese investor buys $10M in shares of Durham's Argos

Lummy+Argos - JPG.jpgArgos Therapeutics, Inc. (Nasdaq: ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, and Lummy (Hong Kong) Co. Ltd., a wholly owned subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. entered into a license agreement.

Under the terms of the agreement, Lummy HK will license from Argos the rights to manufacture, develop and commercialize AGS-003, Argos' investigational immunotherapy for the treatment of cancer, in China, Hong Kong, Taiwan and Macau.

To see a list of investors from China similar to Lummy HK, check the Chinese Investors Directory

More details follows

April 30, 2015 |  Filed under

Previous Post: Skolkovo Foundation and Cybernaut Investment Group setting up a $200 million joint venture fund
Next Post: Three Chinese investment firms invested $35 million in Silicon Valley firm Scanadu

| About Us

SinaBeat.com provides insight, analysis and research on private investors from China since 2012.

We cover Private Equity, Venture Capital, Real Estate and Institutional Investors from China, Hong Kong and Macau.

Our Chinese Investors Directory can be used as a reliable source on information about investors from China.

|Subscribe to mailing list

Enter your email address:

Careers  |  Sponsorship |  Sitemap |  Terms  |  Privacy Policy

Copyright 2007 - 2019     SinaBeat.com

Follow us: RSS  |   SinaBeat on Twitter  |   SinaBeat on Facebook  |   SinaBeat on Google+  |   SinaBeat on LinkedIn